Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Exponent, Inc.    EXPO

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 01/19 10:00:00 pm
73.55 USD   +1.52%
01/19 Exponent to Announce Fourth Quarter and Fiscal Year 2017 Results ..
01/09 EXPONENT : Red Muddy Waters
01/06 EXPONENT : American Meteorological Society Annual Meeting
News SummaryMost relevantAll newsSector newsTweets

Exponent : Society of Environmental Toxicology and Chemistry (SETAC) Annual Meeting

share with twitter share with LinkedIn share with facebook
share via e-mail
11/11/2017 | 01:09am CET
Exponent scientists will be presenting and chairing sessions at the 38th Annual Meeting of the Society of Environmental Toxicology and Chemistry (SETAC) November 12 through November 16, 2017 in Minneapolis, Minnesota.

The theme of the 2017 meeting is, 'Toward a Superior Future: Advancing Science for a Sustainable Environment.' The conference will allow attendees to share and exchange information and ideas to help develop and find solutions to the world's most challenging environmental problems. Over 2,400 scientists from over 40 countries will be in attendance.

SETAC is a non-profit, worldwide professional society whose mission is to support the development of principles and practices for protection, enhancement and management of sustainable environmental quality and ecosystem integrity.

For more information, please see the event website and visit us at Booth #507.

Exponent Platform and Poster Presentations (download our Presentation Handout).
Session Chairs

  • Susan Kane Driscoll: Microplastics in the Aquatic Environment: Fate and Effects
  • Jane Staveley: Pharmaceuticals in the Environment - Potential Environmental and Human Health Impacts

Monday, November 13 - Platform
  • Advancements in Technologies Often Change Previous Norms for Recycling Strategies
    - William Goodfellow, Yoko Masue-Slowey
  • Application of Food Web Models at Superfund Sites: Legal and Political Implications
    - Kirk O'Reilly
  • Addressing White Hat Bias: Lessons from Environmental Litigation
    - Katherine Palmquist
  • Scientific Integrity Issues in Environmental Toxicology
    - Anne Fairbrother and William Goodfellow

Tuesday, November 14 - Platform
  • Toxicity Assessments for NPDES Compliance: Traditional TSD Methods versus the TST Approach
    - William Goodfellow, Susan Paulsen, Katie Marjanovic

Tuesday, November 14 - Posters
  • How Statistical Artifacts Affect the Reliability of Toxicity Thresholds Calculated from Distribution Tails of Field Monitoring Data
    - Roxolana Kashuba, William Goodfellow
  • A Metabolomics Evaluation of Oxygen Containing Compounds Identified In Groundwater from Petroleum Fuel Release Sites
    - Kirk O'Reilly, Sungwoo Ahn

Wednesday, November 15 - Platform
  • PAH Source Identification in Urban Settings: Avoiding the Sin of Oversimplification of Pyrogenic Sources
    - Jaana Pietari, Tarek Saba, and Paul Boehm
  • Application of Receptor Models to Characterize Sources of PAHs in Urban Sediment: Use of Site Specific versus Generic Source Profiles
    - Kirk O'Reilly
Wednesday, November 15 - Posters
  • Use of Read-Across for Testing Estrogen, Androgen, Thyroid, and Steroidogenesis Pathways in Vertebrate Ecological Receptors
    - Margaret McArdle, Jane Staveley, and Elaine Freeman
  • Laboratory, Field, and Analytical Procedures for Using Passive Sampling in the Evaluation of Contaminated Sediments: User's Manual Overview
    - Susan Kane Driscoll
  • Tracking PAH Sources to the Gowanus Canal Superfund Site
    - Tarek Saba, Linda Cook, Natalie Johnson, Jaana Pietari, and Paul Boehm

Thursday, November 16 - Platform
  • Assessing Ecological Risk from the use of a Veterinary Medicinal Product in Cattle: Innovative Approaches for Wildlife Exposure Assessment
    - Josie Nusz and Jane Staveley
  • Environmental Assessment of a Veterinary Drug (Revalor-XR) Containing Trenbolone Acetate and 17β-Estradiol
    - Jane Staveley, Qingli Ma, and Jane Ma

Thursday, November 16 - Posters
  • Groundwater and Surface Water Exposure Assessments of a Veterinary Drug (Revalor-XR) Containing Trenbolone Acetate and 17β-Estradiol
    - Qingli Ma, Jane Staveley, Jane Ma

Exponent Inc. published this content on 12 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 November 2017 00:08:07 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EXPONENT, INC.
01/19 Exponent to Announce Fourth Quarter and Fiscal Year 2017 Results and Host Qua..
01/09 EXPONENT : Red Muddy Waters
01/06 EXPONENT : American Meteorological Society Annual Meeting
2017 EXPONENT : Consumer Product Safety Commission (CPSC) Picks, Predictions, and Oth..
2017 EXPONENT : Society for Risk Analysis (SRA) Annual Meeting
2017 EXPONENT, INC. (NASDAQ : EXPO) Files An 8-K Departure of Directors or Certain Of..
2017 EXPONENT INC : Change in Directors or Principal Officers (form 8-K)
2017 Exponent Announces 2018 Succession Plan
2017 EXPONENT : Annual Christmas Tree Burn
2017 EXPONENT : Biocides Europe 2017
More news
News from SeekingAlpha
01/16 DIVIDEND CHALLENGERS (AND NEAR-CHALL : 153 Increases Expected By The End Of Marc..
2017 102 Dividend Growth Stocks Going Ex-Dividend Next Week
2017 Exponent's (EXPO) CEO Paul Johnston on Q3 2017 Results - Earnings Call Transc..
2017 Exponent declares $0.21 dividend
2017 Exponent beats by $0.09, beats on revenue
Financials ($)
Sales 2017 343 M
EBIT 2017 69,6 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 5,53x
Capi. / Sales 2018 5,23x
Capitalization 1 897 M
Duration : Period :
Exponent, Inc. Technical Analysis Chart | EXPO | US30214U1025 | 4-Traders
Technical analysis trends EXPONENT, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 4
Average target price 76,3 $
Spread / Average Target 3,8%
Paul R. Johnston Chief Executive Officer & Director
Catherine Ford Corrigan President
Michael R. Gaulke Chairman
Richard L. Schlenker Chief Financial Officer, Secretary & Executive VP
Subbaiah V. Malladi Chief Technical Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXPONENT, INC.2.88%1 897
VANTIV INC5.90%13 995